Anti-Müllerian hormone levels and breast cancer risk in the study of women’s health across the nation
Purpose The relation of premenopausal anti-Müllerian hormone (AMH) levels with breast cancer risk has been evaluated in a few studies, but primarily in non-Hispanic White women. Methods We evaluated the association of AMH levels with breast cancer risk in Study of Women’s Health Across the Nation (S...
Gespeichert in:
| Veröffentlicht in: | Cancer causes & control 2022-08, Vol.33 (8), p.1039-1046 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1046 |
|---|---|
| container_issue | 8 |
| container_start_page | 1039 |
| container_title | Cancer causes & control |
| container_volume | 33 |
| creator | Grimes, Nydjie P. Bertone-Johnson, Elizabeth R. Whitcomb, Brian W. Sievert, Lynnette L. Crawford, Sybil L. Gold, Ellen B. Avis, Nancy E. Greendale, Gail A. Santoro, Nanette Habel, Laurel A. Reeves, Katherine W. |
| description | Purpose
The relation of premenopausal anti-Müllerian hormone (AMH) levels with breast cancer risk has been evaluated in a few studies, but primarily in non-Hispanic White women.
Methods
We evaluated the association of AMH levels with breast cancer risk in Study of Women’s Health Across the Nation (SWAN), a multi-ethnic cohort of women. At enrollment, participants had an intact uterus and ≥ 1 ovary, and ≥ 1 menstrual period in the last 3 months. AMH at first measurement was assessed in 1,529 pre- or perimenopausal women using a high-sensitivity ELISA assay; values were natural log transformed. Breast cancer diagnoses were assessed at enrollment and subsequent follow-up visits through 2018 (median 6.1 years).
Results
In total, 84 women reported an incident breast cancer diagnosis. In multivariable Cox regression models adjusting for age, race and ethnicity, body mass index, and other factors, higher AMH levels were associated with a non-significant increased breast cancer risk. Compared to women in the 1st quartile, the hazard ratio (95% confidence interval) for women in the 4th quartile was 1.77 (0.87–3.60).
Conclusion
Our results did not suggest a significant association between AMH and breast cancer risk; however, estimates were consistent with prior studies that reported positive associations. |
| doi_str_mv | 10.1007/s10552-022-01596-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10683710</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2682783546</sourcerecordid><originalsourceid>FETCH-LOGICAL-c359t-892351961d49c2f7adbead420b21113d12d5968a341ce12f61b42333b86312413</originalsourceid><addsrcrecordid>eNp9kc1u1TAQhS0EopfCC7CyxIZNwDOOnWSFqoo_qYgNrC0nmTQujl3spKg7XoN3Yceb8CS491YgWLAYzWK-czQzh7HHIJ6BEM3zDEIprASWAtXpSt1hO1CNrBpEdZftRKeaSmEtj9iDnC-EEEqjuM-OpGp0q2vcsfkkrK569-O795ScDXyOaYmBuKcr8pnbMPI-kc0rH2wYKPHk8ifuAl9n4nndxmseJ_4lLhR-fv2W-UzWrzO3Q4o576FgVxfDQ3Zvsj7To9t-zD6-evnh9E119v7129OTs2qQqlurtkOpoNMw1t2AU2PHnuxYo-gRAOQIOJZLWytrGAhw0tDXKKXsWy0Ba5DH7MXB93LrFxoHCmuy3lwmt9h0baJ15u9JcLM5j1cGhG5lA6I4PL11SPHzRnk1i8sDeW8DxS0b1C02rVS1LuiTf9CLuKVQ7ruhyoM1AhYKD9T-J4mm39uAMDdJmkOSpiRp9kkaVUTyIMoFDueU_lj_R_ULiRGg5Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2686426212</pqid></control><display><type>article</type><title>Anti-Müllerian hormone levels and breast cancer risk in the study of women’s health across the nation</title><source>SpringerLink Journals - AutoHoldings</source><creator>Grimes, Nydjie P. ; Bertone-Johnson, Elizabeth R. ; Whitcomb, Brian W. ; Sievert, Lynnette L. ; Crawford, Sybil L. ; Gold, Ellen B. ; Avis, Nancy E. ; Greendale, Gail A. ; Santoro, Nanette ; Habel, Laurel A. ; Reeves, Katherine W.</creator><creatorcontrib>Grimes, Nydjie P. ; Bertone-Johnson, Elizabeth R. ; Whitcomb, Brian W. ; Sievert, Lynnette L. ; Crawford, Sybil L. ; Gold, Ellen B. ; Avis, Nancy E. ; Greendale, Gail A. ; Santoro, Nanette ; Habel, Laurel A. ; Reeves, Katherine W.</creatorcontrib><description>Purpose
The relation of premenopausal anti-Müllerian hormone (AMH) levels with breast cancer risk has been evaluated in a few studies, but primarily in non-Hispanic White women.
Methods
We evaluated the association of AMH levels with breast cancer risk in Study of Women’s Health Across the Nation (SWAN), a multi-ethnic cohort of women. At enrollment, participants had an intact uterus and ≥ 1 ovary, and ≥ 1 menstrual period in the last 3 months. AMH at first measurement was assessed in 1,529 pre- or perimenopausal women using a high-sensitivity ELISA assay; values were natural log transformed. Breast cancer diagnoses were assessed at enrollment and subsequent follow-up visits through 2018 (median 6.1 years).
Results
In total, 84 women reported an incident breast cancer diagnosis. In multivariable Cox regression models adjusting for age, race and ethnicity, body mass index, and other factors, higher AMH levels were associated with a non-significant increased breast cancer risk. Compared to women in the 1st quartile, the hazard ratio (95% confidence interval) for women in the 4th quartile was 1.77 (0.87–3.60).
Conclusion
Our results did not suggest a significant association between AMH and breast cancer risk; however, estimates were consistent with prior studies that reported positive associations.</description><identifier>ISSN: 0957-5243</identifier><identifier>EISSN: 1573-7225</identifier><identifier>DOI: 10.1007/s10552-022-01596-5</identifier><identifier>PMID: 35768642</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Biomedical and Life Sciences ; Biomedicine ; Body mass ; Body mass index ; Body size ; Breast cancer ; Cancer Research ; Confidence intervals ; Enzyme-linked immunosorbent assay ; Epidemiology ; Evaluation ; Health risks ; Hematology ; Menstruation ; Minority & ethnic groups ; Oncology ; Original Paper ; Public Health ; Regression analysis ; Risk ; Statistical analysis ; Uterus ; Womens health</subject><ispartof>Cancer causes & control, 2022-08, Vol.33 (8), p.1039-1046</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022</rights><rights>The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c359t-892351961d49c2f7adbead420b21113d12d5968a341ce12f61b42333b86312413</cites><orcidid>0000-0002-3698-1942</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10552-022-01596-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10552-022-01596-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids></links><search><creatorcontrib>Grimes, Nydjie P.</creatorcontrib><creatorcontrib>Bertone-Johnson, Elizabeth R.</creatorcontrib><creatorcontrib>Whitcomb, Brian W.</creatorcontrib><creatorcontrib>Sievert, Lynnette L.</creatorcontrib><creatorcontrib>Crawford, Sybil L.</creatorcontrib><creatorcontrib>Gold, Ellen B.</creatorcontrib><creatorcontrib>Avis, Nancy E.</creatorcontrib><creatorcontrib>Greendale, Gail A.</creatorcontrib><creatorcontrib>Santoro, Nanette</creatorcontrib><creatorcontrib>Habel, Laurel A.</creatorcontrib><creatorcontrib>Reeves, Katherine W.</creatorcontrib><title>Anti-Müllerian hormone levels and breast cancer risk in the study of women’s health across the nation</title><title>Cancer causes & control</title><addtitle>Cancer Causes Control</addtitle><description>Purpose
The relation of premenopausal anti-Müllerian hormone (AMH) levels with breast cancer risk has been evaluated in a few studies, but primarily in non-Hispanic White women.
Methods
We evaluated the association of AMH levels with breast cancer risk in Study of Women’s Health Across the Nation (SWAN), a multi-ethnic cohort of women. At enrollment, participants had an intact uterus and ≥ 1 ovary, and ≥ 1 menstrual period in the last 3 months. AMH at first measurement was assessed in 1,529 pre- or perimenopausal women using a high-sensitivity ELISA assay; values were natural log transformed. Breast cancer diagnoses were assessed at enrollment and subsequent follow-up visits through 2018 (median 6.1 years).
Results
In total, 84 women reported an incident breast cancer diagnosis. In multivariable Cox regression models adjusting for age, race and ethnicity, body mass index, and other factors, higher AMH levels were associated with a non-significant increased breast cancer risk. Compared to women in the 1st quartile, the hazard ratio (95% confidence interval) for women in the 4th quartile was 1.77 (0.87–3.60).
Conclusion
Our results did not suggest a significant association between AMH and breast cancer risk; however, estimates were consistent with prior studies that reported positive associations.</description><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Body mass</subject><subject>Body mass index</subject><subject>Body size</subject><subject>Breast cancer</subject><subject>Cancer Research</subject><subject>Confidence intervals</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Epidemiology</subject><subject>Evaluation</subject><subject>Health risks</subject><subject>Hematology</subject><subject>Menstruation</subject><subject>Minority & ethnic groups</subject><subject>Oncology</subject><subject>Original Paper</subject><subject>Public Health</subject><subject>Regression analysis</subject><subject>Risk</subject><subject>Statistical analysis</subject><subject>Uterus</subject><subject>Womens health</subject><issn>0957-5243</issn><issn>1573-7225</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kc1u1TAQhS0EopfCC7CyxIZNwDOOnWSFqoo_qYgNrC0nmTQujl3spKg7XoN3Yceb8CS491YgWLAYzWK-czQzh7HHIJ6BEM3zDEIprASWAtXpSt1hO1CNrBpEdZftRKeaSmEtj9iDnC-EEEqjuM-OpGp0q2vcsfkkrK569-O795ScDXyOaYmBuKcr8pnbMPI-kc0rH2wYKPHk8ifuAl9n4nndxmseJ_4lLhR-fv2W-UzWrzO3Q4o576FgVxfDQ3Zvsj7To9t-zD6-evnh9E119v7129OTs2qQqlurtkOpoNMw1t2AU2PHnuxYo-gRAOQIOJZLWytrGAhw0tDXKKXsWy0Ba5DH7MXB93LrFxoHCmuy3lwmt9h0baJ15u9JcLM5j1cGhG5lA6I4PL11SPHzRnk1i8sDeW8DxS0b1C02rVS1LuiTf9CLuKVQ7ruhyoM1AhYKD9T-J4mm39uAMDdJmkOSpiRp9kkaVUTyIMoFDueU_lj_R_ULiRGg5Q</recordid><startdate>20220801</startdate><enddate>20220801</enddate><creator>Grimes, Nydjie P.</creator><creator>Bertone-Johnson, Elizabeth R.</creator><creator>Whitcomb, Brian W.</creator><creator>Sievert, Lynnette L.</creator><creator>Crawford, Sybil L.</creator><creator>Gold, Ellen B.</creator><creator>Avis, Nancy E.</creator><creator>Greendale, Gail A.</creator><creator>Santoro, Nanette</creator><creator>Habel, Laurel A.</creator><creator>Reeves, Katherine W.</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3698-1942</orcidid></search><sort><creationdate>20220801</creationdate><title>Anti-Müllerian hormone levels and breast cancer risk in the study of women’s health across the nation</title><author>Grimes, Nydjie P. ; Bertone-Johnson, Elizabeth R. ; Whitcomb, Brian W. ; Sievert, Lynnette L. ; Crawford, Sybil L. ; Gold, Ellen B. ; Avis, Nancy E. ; Greendale, Gail A. ; Santoro, Nanette ; Habel, Laurel A. ; Reeves, Katherine W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c359t-892351961d49c2f7adbead420b21113d12d5968a341ce12f61b42333b86312413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Body mass</topic><topic>Body mass index</topic><topic>Body size</topic><topic>Breast cancer</topic><topic>Cancer Research</topic><topic>Confidence intervals</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Epidemiology</topic><topic>Evaluation</topic><topic>Health risks</topic><topic>Hematology</topic><topic>Menstruation</topic><topic>Minority & ethnic groups</topic><topic>Oncology</topic><topic>Original Paper</topic><topic>Public Health</topic><topic>Regression analysis</topic><topic>Risk</topic><topic>Statistical analysis</topic><topic>Uterus</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Grimes, Nydjie P.</creatorcontrib><creatorcontrib>Bertone-Johnson, Elizabeth R.</creatorcontrib><creatorcontrib>Whitcomb, Brian W.</creatorcontrib><creatorcontrib>Sievert, Lynnette L.</creatorcontrib><creatorcontrib>Crawford, Sybil L.</creatorcontrib><creatorcontrib>Gold, Ellen B.</creatorcontrib><creatorcontrib>Avis, Nancy E.</creatorcontrib><creatorcontrib>Greendale, Gail A.</creatorcontrib><creatorcontrib>Santoro, Nanette</creatorcontrib><creatorcontrib>Habel, Laurel A.</creatorcontrib><creatorcontrib>Reeves, Katherine W.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer causes & control</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Grimes, Nydjie P.</au><au>Bertone-Johnson, Elizabeth R.</au><au>Whitcomb, Brian W.</au><au>Sievert, Lynnette L.</au><au>Crawford, Sybil L.</au><au>Gold, Ellen B.</au><au>Avis, Nancy E.</au><au>Greendale, Gail A.</au><au>Santoro, Nanette</au><au>Habel, Laurel A.</au><au>Reeves, Katherine W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-Müllerian hormone levels and breast cancer risk in the study of women’s health across the nation</atitle><jtitle>Cancer causes & control</jtitle><stitle>Cancer Causes Control</stitle><date>2022-08-01</date><risdate>2022</risdate><volume>33</volume><issue>8</issue><spage>1039</spage><epage>1046</epage><pages>1039-1046</pages><issn>0957-5243</issn><eissn>1573-7225</eissn><abstract>Purpose
The relation of premenopausal anti-Müllerian hormone (AMH) levels with breast cancer risk has been evaluated in a few studies, but primarily in non-Hispanic White women.
Methods
We evaluated the association of AMH levels with breast cancer risk in Study of Women’s Health Across the Nation (SWAN), a multi-ethnic cohort of women. At enrollment, participants had an intact uterus and ≥ 1 ovary, and ≥ 1 menstrual period in the last 3 months. AMH at first measurement was assessed in 1,529 pre- or perimenopausal women using a high-sensitivity ELISA assay; values were natural log transformed. Breast cancer diagnoses were assessed at enrollment and subsequent follow-up visits through 2018 (median 6.1 years).
Results
In total, 84 women reported an incident breast cancer diagnosis. In multivariable Cox regression models adjusting for age, race and ethnicity, body mass index, and other factors, higher AMH levels were associated with a non-significant increased breast cancer risk. Compared to women in the 1st quartile, the hazard ratio (95% confidence interval) for women in the 4th quartile was 1.77 (0.87–3.60).
Conclusion
Our results did not suggest a significant association between AMH and breast cancer risk; however, estimates were consistent with prior studies that reported positive associations.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>35768642</pmid><doi>10.1007/s10552-022-01596-5</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-3698-1942</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0957-5243 |
| ispartof | Cancer causes & control, 2022-08, Vol.33 (8), p.1039-1046 |
| issn | 0957-5243 1573-7225 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10683710 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Biomedical and Life Sciences Biomedicine Body mass Body mass index Body size Breast cancer Cancer Research Confidence intervals Enzyme-linked immunosorbent assay Epidemiology Evaluation Health risks Hematology Menstruation Minority & ethnic groups Oncology Original Paper Public Health Regression analysis Risk Statistical analysis Uterus Womens health |
| title | Anti-Müllerian hormone levels and breast cancer risk in the study of women’s health across the nation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T01%3A15%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-M%C3%BCllerian%20hormone%20levels%20and%20breast%20cancer%20risk%20in%20the%20study%20of%20women%E2%80%99s%20health%20across%20the%20nation&rft.jtitle=Cancer%20causes%20&%20control&rft.au=Grimes,%20Nydjie%20P.&rft.date=2022-08-01&rft.volume=33&rft.issue=8&rft.spage=1039&rft.epage=1046&rft.pages=1039-1046&rft.issn=0957-5243&rft.eissn=1573-7225&rft_id=info:doi/10.1007/s10552-022-01596-5&rft_dat=%3Cproquest_pubme%3E2682783546%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2686426212&rft_id=info:pmid/35768642&rfr_iscdi=true |